RE
$11.99
+0.27
(+2.30%)
As of Oct 22, 2026, 9:29 PM EDT · cached
Price history
Replimune Group Inc (REPL) is trading up at $11.99 (+2.30%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: July 20, 2018 · $15.00 offering · NASDAQ · View IPO details →
Replimune Group Inc net income history (FY2017–FY2026)
Net income
| FY2017Mar 2017 | FY2018Mar 2018 | FY2019Mar 2019 | FY2020Mar 2020 | FY2021Mar 2021 | FY2022Mar 2022 | FY2023Mar 2023 | FY2024Mar 2024 | FY2025Mar 2025 | FY2026Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Operating income | −$9.65M | −$19.2M | −$30.9M | −$56.2M | −$80.0M | −$118.3M | −$177.1M | −$234.8M | −$261.6M | −$319.9M |
| Net income | −$7.70M | −$19.7M | −$30.8M | −$52.6M | −$80.9M | −$118.0M | −$174.3M | −$215.8M | −$247.3M | −$313.9M |
| EPS (diluted) | −$1.55 | −$3.96 | −$1.33 | −$1.54 | −$1.75 | −$2.26 | −$2.99 | −$3.24 | −$3.07 | −$3.38 |
| Balance sheet | ||||||||||
| Cash and equivalents | $20.7M | $17.6M | $25.7M | $59.5M | $182.5M | $105.9M | $146.6M | $74.5M | $111.1M | $209.0M |
| Total assets | — | $65.2M | $154.3M | $234.1M | $543.1M | $461.2M | $646.6M | $487.7M | $551.3M | $332.4M |
| Total liabilities | — | $6.86M | $16.5M | $50.4M | $44.4M | $50.0M | $91.3M | $113.2M | $135.5M | $166.2M |
| Long-term debt | — | — | — | $9.80M | — | $0 | $28.6M | $44.8M | $46.4M | $83.3M |
| Shareholders' equity | −$11.5M | −$28.1M | $137.9M | $183.7M | $498.7M | $411.2M | $555.3M | $374.5M | $415.8M | $166.2M |
| Cash flow | ||||||||||
| Operating cash flow | −$7.08M | −$16.0M | −$25.4M | −$60.6M | −$61.4M | −$82.2M | −$128.1M | −$185.5M | −$192.3M | −$280.3M |
| Capital expenditure | $238.0K | $136.0K | $2.60M | $6.54M | $2.39M | $2.34M | $2.27M | $5.66M | $6.69M | $4.22M |
| Free cash flow | −$7.32M | −$16.1M | −$28.0M | −$67.1M | −$63.8M | −$84.5M | −$130.3M | −$191.1M | −$198.9M | −$284.6M |
Net income
| Q2 FY25Sep 2024 | Q3 FY25Dec 2024 | Q4 FY25†Mar 2025 | Q1 FY26Jun 2025 | Q2 FY26Sep 2025 | Q3 FY26Dec 2025 | Q4 FY26†Mar 2026 | Q1 FY27Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$58.9M | −$66.0M | −$79.3M | −$90.4M | −$84.3M | −$71.9M | −$73.3M | −$68.2M |
| Net income | −$53.1M | −$66.3M | −$74.1M | −$86.7M | −$83.1M | −$70.9M | −$73.2M | −$69.8M |
| EPS (diluted) | −$0.68 | −$0.79 | −$0.82 | −$0.95 | −$0.90 | −$0.77 | −$0.76 | −$0.72 |
| Balance sheet | ||||||||
| Cash and equivalents | $113.5M | $172.2M | $111.1M | $97.4M | $102.3M | $123.0M | $209.0M | $185.4M |
| Total assets | $498.2M | $603.6M | $551.3M | $469.5M | $389.4M | $333.6M | $332.4M | $252.4M |
| Total liabilities | $116.7M | $121.3M | $135.5M | $132.8M | $126.1M | $123.1M | $166.2M | $146.8M |
| Long-term debt | $45.6M | $46.0M | $46.4M | $46.8M | $47.2M | $47.6M | $83.3M | $84.1M |
| Shareholders' equity | $381.5M | $482.4M | $415.8M | $336.7M | $263.3M | $210.5M | $166.2M | $105.6M |
| Cash flow | ||||||||
| Operating cash flow | −$38.6M | −$50.7M | −$53.7M | −$77.0M | −$81.2M | −$66.0M | −$56.2M | −$75.7M |
| Capital expenditure | $2.08M | $1.80M | $1.13M | $2.74M | $1.34M | $135.0K | $5.00K | $6.00K |
| Free cash flow | −$40.7M | −$52.5M | −$54.9M | −$79.8M | −$82.6M | −$66.1M | −$56.2M | −$75.7M |
From Replimune Group Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in March. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Replimune Group Inc
- Headquarters
- Woburn, Massachusetts From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International